SEBIVO 600MG TABLET

SEBIVO 600MG TABLET is an antiviral medicine used to treat viral infections. SEBIVO 600MG TABLET is used in the treatment of chronic Hepatitis B infection in patients with evidence of viral replication. It is a serious infection caused by the Hepatitis B virus. It is a contagious infection that spreads from person to person and affects the liver. SEBIVO 600MG TABLET is only used in treating the infection. It does not cure or prevent further liver complications.

SEBIVO 600MG TABLET contains Telbivudine, which belongs to the class of nucleoside analogues. It works by blocking the activity of the hepatitis B virus DNA Polymerase enzyme in the liver cells. This causes DNA termination and reduces the amount of hepatitis B virus in the body.

SEBIVO 600MG TABLET may cause certain side effects such as headache, abdominal pain, nausea, diarrhoea, dizziness, vomiting, cough, abdominal pain, fever, myalgia, back pain and fatigue. Most of these side effects do not require medical attention and gradually resolve over time. However, if the side effects persist, please consult your doctor. It should be taken with or after food to avoid any stomach upset. Use it as suggested by your doctor. Your doctor will decide the dose of the medicine based on your health condition.

SEBIVO 600MG TABLET should be avoided if you are allergic to it. Caution should be exercised in conditions like liver cirrhosis, liver cancer, or kidney problems. SEBIVO 600MG TABLET may cause lactic acidosis, severe hepatomegaly with steatosis, myopathy, and peripheral neuropathy in some patients. Stopping the treatment with SEBIVO 600MG TABLET may lead to acute exacerbations of Hepatitis B infection. Hence, careful monitoring should be done during and after the treatment. If you are pregnant or breastfeeding, inform your doctor before starting treatment with this medicine. SEBIVO 600MG TABLET is not recommended for children below 16 years of age as efficacy and safety have not been established.

SEBIVO 600MG TABLET contains Telbivudine, which belongs to the class of nucleotide analogues. It works by blocking the activity of the hepatitis B virus DNA Polymerase enzyme in the liver cells, which is essential for the virus to grow. This causes DNA termination and, therefore, reduces the amount of hepatitis B virus in the body. This medicine only treats the HBV infection but does not cure it or prevent further liver complications.

Avoid taking SEBIVO 600MG TABLET and inform your doctor if you are allergic to it. Keep your doctor informed about your complete medical history to rule out any serious side effects. If you are pregnant or breastfeeding, inform your doctor before starting treatment with this medicine. Caution should be exercised in patients having underlying conditions like liver cirrhosis, HIV infection, liver cancer, or kidney problems before starting the treatment. SEBIVO 600MG TABLET may cause lactic acidosis, severe hepatomegaly with steatosis, myopathy, peripheral neuropathy and acute exacerbations of Hepatitis B, HIV infection, lactic acidosis and severe hepatomegaly with steatosis, as it may cause serious side effects. It is advised not to stop taking SEBIVO 600MG TABLET abruptly, as it can cause a recurrence of severe acute exacerbations of hepatitis or may also lead to cirrhosis. SEBIVO 600MG TABLET is not recommended for children below 16 years of age as efficacy and safety have not been established. SEBIVO 600MG TABLET should not be taken along with pegylated interferon alfa-2a as it can cause peripheral neuropathy. Hence, informing your doctor about your complete medication history before taking this medicine is advised.

• Sudden withdrawal of SEBIVO 600MG TABLET should be avoided as it can cause severe acute exacerbations of hepatitis or other serious side effects.
• Frequent monitoring of liver and kidney function tests are required while on treatment with SEBIVO 600MG TABLET to monitor liver and kidney functions.
• Patients should be observed carefully for any changes in the liver function test even after the completion of the treatment course.